Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Manitoba

$18,000.00

Models and methods of statistical dependence with applications in clinical trials and risk management

FY 2021-22

Summary
Bayesian method; Copula; Design of clinical trials; Dynamic risk measures; Markov decision processes; Personalized medicine; Response adaptive clinical trials; Seamless Phase I/II clinical trials; Stochastic dependence; Value at risk
Program
Discovery Grants Program - Individual
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2018-05362
Name nom
Wang, Xikui
Department département
Statistics
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2018
Award amount
18000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1508
Committee name en
Mathematics and Statistics
Committee name fr
Mathématiques et statistique
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3004
Research subject group en
Statistics and probability
Research subject group fr
Statistique et probabilité
Research subject en
Applied statistics
Research subject fr
Statistique appliquée
Installment
inst:4
Partie
1
Nb partie
5
Application title
Models and methods of statistical dependence with applications in clinical trials and risk management
Keyword
NSERC
Application summary
Bayesian method; Copula; Design of clinical trials; Dynamic risk measures; Markov decision processes; Personalized medicine; Response adaptive clinical trials; Seamless Phase I/II clinical trials; Stochastic dependence; Value at risk